For Media Inquiries:
The Purchaser Business Group on Health (PBGH) commends congressional negotiators who struck a landmark deal to reform the prescription drug market.
The Purchaser Business Group on Health is profoundly disappointed that the budget reconciliation framework announced today by President Biden omits any policies to deal with unaffordable prescription drugs.
On Sept. 30, the Departments of Health and Human Services, Labor and Treasury, released an interim final rule (IFR) implementing the No Surprises Act.
Covered California, the California Public Employees’ Retirement System (CalPERS) and the Purchaser Business Group on Health (PBGH) are partnering to launch a pilot program to promote improvement in primary care which will benefit all Californians.
Patients and employers urge the House Ways and Means and Energy and Commerce Committees to move forward with H.R. 3, a bill that will empower Medicare to negotiate lower drug prices on behalf of Americans.
Congressional leaders are currently drafting legislation that would allow the federal government to negotiate the price of high-cost drugs and those newly entering the market.
The settlement agreement achieved in the Sutter Health case, along with the injunctive relief, will have a significant and beneficial economic impact.
Addressing health care costs, and in particular the cost of prescription drugs, is an economic issue. Earnings siphoned off by health care costs limit job creation and wage growth, divert investment and cripple competitiveness and innovation.
We are very pleased that the Biden administration is signaling its intention to aggressively implement the previous administration’s hospital price transparency rule.
The Purchaser Business Group on Health (PBGH) has announced the addition of four new board members.